Literature DB >> 27288458

Disruption of the astrocytic TNFR1-GDNF axis accelerates motor neuron degeneration and disease progression in amyotrophic lateral sclerosis.

Liliana Brambilla1, Giulia Guidotti1, Francesca Martorana1, Anand M Iyer2, Eleonora Aronica2, Chiara F Valori3, Daniela Rossi4.   

Abstract

Considerable evidence indicates that neurodegeneration in amyotrophic lateral sclerosis (ALS) can be conditioned by a deleterious interplay between motor neurons and astrocytes. Astrocytes are the major glial component in the central nervous system (CNS) and fulfill several activities that are essential to preserve CNS homeostasis. In physiological and pathological conditions, astrocytes secrete a wide range of factors by which they exert multimodal influences on their cellular neighbours. Among others, astrocytes can secrete glial cell line-derived neurotrophic factor (GDNF), one of the most potent protective agents for motor neurons. This suggests that the modulation of the endogenous mechanisms that control the production of astrocytic GDNF may have therapeutic implications in motor neuron diseases, particularly ALS. In this study, we identified TNF receptor 1 (TNFR1) signalling as a major promoter of GDNF synthesis/release from human and mouse spinal cord astrocytes in vitro and in vivo To determine whether endogenously produced TNFα can also trigger the synthesis of GDNF in the nervous system, we then focused on SOD1G93A ALS transgenic mice, whose affected tissues spontaneously exhibit high levels of TNFα and its receptor 1 at the onset and symptomatic stage of the disease. In SOD1G93A spinal cords, we verified a strict correlation in the expression of the TNFα, TNFR1 and GDNF triad at different stages of disease progression. Yet, ablation of TNFR1 completely abolished GDNF rises in both SOD1G93A astrocytes and spinal cords, a condition that accelerated motor neuron degeneration and disease progression. Our data suggest that the astrocytic TNFR1-GDNF axis represents a novel target for therapeutic intervention in ALS.
© The Author 2016. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27288458     DOI: 10.1093/hmg/ddw161

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  19 in total

1.  Noncompetitive inhibitors of TNFR1 probe conformational activation states.

Authors:  Chih Hung Lo; Tory M Schaaf; Benjamin D Grant; Colin Kin-Wye Lim; Prachi Bawaskar; Courtney C Aldrich; David D Thomas; Jonathan N Sachs
Journal:  Sci Signal       Date:  2019-07-30       Impact factor: 8.192

Review 2.  Role and Therapeutic Potential of Astrocytes in Amyotrophic Lateral Sclerosis.

Authors:  Mariana Pehar; Benjamin A Harlan; Kelby M Killoy; Marcelo R Vargas
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

3.  MicroRNA-204 silencing relieves pain of cervical spondylotic radiculopathy by targeting GDNF.

Authors:  Wen-Sheng Shen; Cun-Feng Li; Zhi-Shui Zhou; Nan-Nan Zhai; Lu-Ping Pan
Journal:  Gene Ther       Date:  2019-12-09       Impact factor: 5.250

Review 4.  Amyotrophic Lateral Sclerosis, a Multisystem Pathology: Insights into the Role of TNFα.

Authors:  Massimo Tortarolo; Daniele Lo Coco; Pietro Veglianese; Antonio Vallarola; Maria Teresa Giordana; Gabriella Marcon; Ettore Beghi; Marco Poloni; Michael J Strong; Anand M Iyer; Eleonora Aronica; Caterina Bendotti
Journal:  Mediators Inflamm       Date:  2017-09-10       Impact factor: 4.711

5.  Safety and efficacy of human embryonic stem cell-derived astrocytes following intrathecal transplantation in SOD1G93A and NSG animal models.

Authors:  Michal Izrael; Shalom Guy Slutsky; Tamar Admoni; Louisa Cohen; Avital Granit; Arik Hasson; Joseph Itskovitz-Eldor; Lena Krush Paker; Graciela Kuperstein; Neta Lavon; Shiran Yehezkel Ionescu; Leonardo Javier Solmesky; Rachel Zaguri; Alina Zhuravlev; Ella Volman; Judith Chebath; Michel Revel
Journal:  Stem Cell Res Ther       Date:  2018-06-06       Impact factor: 6.832

6.  Dysregulation of Astrocytic HMGB1 Signaling in Amyotrophic Lateral Sclerosis.

Authors:  Liliana Brambilla; Francesca Martorana; Giulia Guidotti; Daniela Rossi
Journal:  Front Neurosci       Date:  2018-08-29       Impact factor: 4.677

7.  Influence of Lineage-Negative Stem Cell Therapy on Articulatory Functions in ALS Patients.

Authors:  Wioletta Pawlukowska; Bartłomiej Baumert; Monika Gołąb-Janowska; Anna Sobuś; Agnieszka Wełnicka; Agnieszka Meller; Karolina Machowska-Sempruch; Alicja Zawiślak; Karolina Łuczkowska; Sławomir Milczarek; Bogumiła Osękowska; Edyta Paczkowska; Iwona Rotter; Przemysław Nowacki; Bogusław Machaliński
Journal:  Stem Cells Int       Date:  2019-06-02       Impact factor: 5.443

Review 8.  Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact.

Authors:  Fabiola De Marchi; Ivana Munitic; Amedeo Amedei; James D Berry; Eva L Feldman; Eleonora Aronica; Giovanni Nardo; Donatienne Van Weehaeghe; Elena Niccolai; Nikolina Prtenjaca; Stacey A Sakowski; Caterina Bendotti; Letizia Mazzini
Journal:  Neurosci Biobehav Rev       Date:  2021-06-19       Impact factor: 9.052

9.  A Role for GDNF and Soluble APP as Biomarkers of Amyotrophic Lateral Sclerosis Pathophysiology.

Authors:  Serena Stanga; Liliana Brambilla; Bernadette Tasiaux; Anh H Dang; Adrian Ivanoiu; Jean-Noël Octave; Daniela Rossi; Vincent van Pesch; Pascal Kienlen-Campard
Journal:  Front Neurol       Date:  2018-05-30       Impact factor: 4.003

10.  Repeated Application of Autologous Bone Marrow-Derived Lineage-Negative Stem/Progenitor Cells-Focus on Immunological Pathways in Patients with ALS.

Authors:  Bartłomiej Baumert; Anna Sobuś; Monika Gołąb-Janowska; Edyta Paczkowska; Karolina Łuczkowska; Dorota Rogińska; Alicja Zawiślak; Sławomir Milczarek; Bogumiła Osękowska; Wioletta Pawlukowska; Agnieszka Meller; Karolina Machowska-Sempruch; Agnieszka Wełnicka; Krzysztof Safranow; Przemysław Nowacki; Bogusław Machaliński
Journal:  Cells       Date:  2020-08-01       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.